4.7 Article

Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia

期刊

BLOOD
卷 140, 期 8, 页码 875-888

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2021015325

关键词

-

资金

  1. American Society of Hematology
  2. Japanese Society of Hematology
  3. Leukemia & Lymphoma Society
  4. National Institutes of Health (NIH) , National Cancer Institute [R01 CA242020, R01 CA251138, R00 CA218896]
  5. National Heart, Lung, and Blood Institute [R01HL128 239, P50 254838]
  6. Edward P. Evans Foundation
  7. Vera and Joseph Dresner Foundation
  8. Naito Foundation
  9. Uehara Memorial Foundation
  10. Senri Life Science Foundation
  11. Sumitomo Foundation
  12. Kanae Foundation
  13. Mitsubishi Foundation
  14. KAKETSUKEN
  15. Bristol Myers Squibb Foundation
  16. JSPS KAKENHI
  17. AMED
  18. [JP20H00537]
  19. [JP20H03717]
  20. [JP21J15620]
  21. [16H06279]
  22. [21ck0106697h0001]

向作者/读者索取更多资源

This study identifies a novel oncogenic RNA-splicing derived isoform of EVI1 that is frequently present in inv(3)/t(3;3) acute myeloid leukemia. It is generated by mutations in the core RNA splicing factor SF3B1, which is commonly cooccurring with inv(3)/t(3;3) genomic alteration. The mutant SF3B1 spliceosome promotes mis-splicing of EVI1 and enhances self-renewal of hematopoietic stem cells, contributing to leukemic transformation.
Detailed genomic and epigenomic analyses of MECOM (the MDS1 and EVI1 complex locus) have revealed that inversion or translocation of chromosome 3 drives inv(3)/t(3;3) myeloid leukemias via structural rearrangement of an enhancer that upregulates transcription of EVI1. Here, we identify a novel, previously unannotated oncogenic RNA-splicing derived isoform of EVI1 that is frequently present in inv(3)/t(3;3) acute myeloid leukemia (AML) and directly contributes to leukemic transformation. This EVI1 isoform is generated by oncogenic mutations in the core RNA splicing factor SF3B1, which is mutated in >30% of inv(3)/t(3;3) myeloid neoplasm patients and thereby represents the single most commonly cooccurring genomic alteration in inv(3)/t(3;3) patients. SF3B1 mutations are statistically uniquely enriched in inv(3)/t(3;3) myeloid neoplasm patients and patient-derived cell lines compared with other forms of AML and promote mis-splicing of EVI1 generating an in-frame insertion of 6 amino acids at the 3' end of the second zinc finger domain of EVI1. Expression of this EVI1 splice variant enhanced the self-renewal of hematopoietic stem cells, and introduction of mutant SF3B1 in mice bearing the humanized inv(3)(q21q26) allele resulted in generation of this novel EVI1 isoform in mice and hastened leukemogenesis in vivo. The mutant SF3B1 spliceosome depends upon an exonic splicing enhancer within EVI1 exon 13 to promote usage of a cryptic branch point and aberrant 3' splice site within intron 12 resulting in the generation of this isoform. These data provide a mechanistic basis for the frequent cooccurrence of SF3B1 mutations as well as new insights into the pathogenesis of myeloid leukemias harboring inv(3)/t(3;3).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据